Ryanodex and Standard of Care
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Exertional Heat Stroke
Conditions
Exertional Heat Stroke
Trial Timeline
Aug 19, 2018 → Aug 14, 2019
NCT ID
NCT03600376About Ryanodex and Standard of Care
Ryanodex and Standard of Care is a phase 3 stage product being developed by Eagle Pharmaceuticals for Exertional Heat Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT03600376. Target conditions include Exertional Heat Stroke.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03600376 | Phase 3 | Completed |
Competing Products
1 competing product in Exertional Heat Stroke
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Definity | Lantheus Holdings | Phase 2/3 | 62 |
Other Products from Eagle Pharmaceuticals
Arm 1 Cataract Surgery performed with remimazolam as sedative + Arm 2 Cataract Surgery performed with standard of care sedativeApproved
77
Placebo + Mesalamine + MesalaminePhase 3
69
CAL02 + PlaceboPhase 2
44
Ryanodex (dantrolene sodium) for injectable suspensionPhase 2
44
Dantrolene sodium for injectable suspensionPhase 2
44